Camber Pharmaceuticals Inc

This week, Camber’s David Smith and Daljeet Singh had the privilege of attending ECRM’s “Cough, Cold, Preventative & Allergy Session” in Chicago. At Camber Consumer Care, we’re proud to offer a diverse range of OTC medications for Allergy, Pain, and Gastrointestinal Relief. Many of our OTC products are available for Private Labeling and Bulk Sale, making them a versatile choice for businesses. Explore our OTC product offerings: https://lnkd.in/eKYm4CGd   #OTCMedications #PrivateLabel #CamberPharma #ECRM

Camber Pharmaceuticals is excited to announce the addition of Nimodipine Oral Solution. Nimodipine Oral Solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition. Nimodipine Oral Solution 60 mg/20 mL (3 mg/mL) is available and packaged in a 16-ounce bottle. To find out more information on Nimodipine Oral Solution, please visit: https://lnkd.in/eASXrCty

With nearly 200 generic, specialty, and OTC medications, Camber is committed to enhancing healthcare accessibility and affordability. Explore some key products in the video below to see how we make a difference in patient care.

Camber added Sildenafil for Oral Suspension to its product portfolio in 2021. Sildenafil for oral suspension is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. This launch reflects Camber’s ongoing commitment to providing innovative treatments that improve patient outcomes.

Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection. Bortezomib for Injection is a proteasome inhibitor indicated for: 1. treatment of adult patients with multiple myeloma 2. treatment of adult patients with mantle cell lymphoma Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial. To find out more information on Bortezomib for Injection please visit: https://lnkd.in/exbT8KXz

At Camber, we are proud to continue expanding our portfolio with solutions that address critical patient needs. In 2023, Camber launched Ibuprofen and Famotidine Tablets. Ibuprofen and Famotidine Tablets, a combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the histamine H2– receptor antagonist famotidine, is indicated for (1) the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and (2) to decrease the risk of developing upper gastrointestinal ulcers, in patients who are taking ibuprofen for those indications.

Depression affects 21 million Americans, according to Mental Health America. In 2023, Camber responded to this widespread public health challenge by launching buPROPion. These bupropion hydrochloride extended-release tablets are an aminoketone antidepressant, indicated for the treatment of major depressive disorder. At Camber, we remain dedicated to making a difference by providing accessible, high-quality medications that address critical health needs.

As we step into 2025, Camber reflects on an inspiring close to the previous year. We were honored to host Dr. B. Partha Saradhi Reddy, Chairman of our parent company, Hetero, for a two-day visit to our New Jersey headquarters in December. Dr. Reddy’s visionary leadership and unwavering commitment to advancing global healthcare continue to inspire our mission. His visit offered invaluable insights into Hetero’s strategic direction and bold vision for the future. With 2025 underway, we are energized for what promises to be one of our most exciting years yet, filled with new generic launches and anticipated ANDA approvals. #genericdrugs #healthcare #hetero

2024 was an outstanding year for Camber Pharmaceuticals, with 36 new generic launches and 45 ANDA approvals. As we look ahead, 2025 promises even greater milestones. Wishing all our associates, partners, and friends a happy and prosperous New Year! Our offices will be closed on Wednesday, January 1.

Camber Pharmaceuticals is excited to announce the addition of Dicyclomine Hydrochloride Capsules, USP. Dicyclomine Hydrochloride Capsules, USP are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome. Dicyclomine Hydrochloride Capsules, USP are available in 10 mg strength, packaged in 100 and 1000 count bottles. To find out more information on Dicyclomine Hydrochloride Capsules, USP please visit: https://lnkd.in/eQtcNziY